Phase 2 N=43 Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome
Dumping Syndrome
Primary: Response Rate in Plasma Glucose Level — 60.5 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=104 Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus
Dyspepsia · Diabetes Mellitus With Gastrointestinal Symptoms
Primary: Mean Intestinal Chemosensitivity to Lipids Perfusion — 0.22; 0.36; 0.55; 0.65 score on a scale — p=0.06
N/A N=62 Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge
Hypoglycemia · Obesity
Primary: Mean Serum Glucose Levels — 123.1; 157.5; 103.2; 138 mg/dl
Phase 4 N=20 Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying
Obesity
Primary: Gastric Emptying Half-time (T 1/2) of Solids — 187; 86 minutes — p=<.001
N/A N=53 Gastroesophageal Reflux Disease (GERD) Before and After Gastric Bypass
Gastroesophageal Reflux Disease · Morbid Obesity
Primary: Number of Participants Presenting Reflux Symptoms — 31; 8; 5 participants — p=<0.001
N/A N=22 Diabetes and Gastric By- Pass
Type 2 Diabetes
Primary: Response in Glucose AUC at Baseline vs. Following Gastric Bypass Surgery — 61647.0; 59476.1 mg/dL*min
N/A N=7 Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia
Postprandial Hypoglycemia
Primary: Mean Plasma Glucose Area Under the Curve (AUC 0-3h) — 22,192.5; 25,207.1; 21,715.9 mg*min/dl
N/A N=30 Ileal Interposition With Sleeve Gastrectomy for Control of Diabetes
Diabetes
Primary: Percentage of Participants Having Remission of Type 2 Diabetes — 76.66 Percentage of Participants
Phase 3 N=292 Functional Dyspepsia Treatment Trial
Dyspepsia and Other Specified Disorders of Function of Stomach
Primary: Self-Report of Adequate Relief of Dyspepsia (Yes/No) For at Least 50% of Weeks 3 -12 of Treatment — 53; 38; 40 percentage of participants — p=0.05
N/A N=5 Gastrectomy, Eating Behaviour and GLP-1
Gastric Cancer · Dumping Syndrome
Primary: Nadir Blood Glucose — 3; 4.4 mmol/l — p=0.008
Phase 4 N=22 Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Hypoglycemia · Evidence of Previous Gastric Surgery
Primary: Plasma Glucose Levels in Response to Mixed Meal Testing - Area Under the Curve for Plasma Glucose — 2828; 2893 mg*min/dL — p=0.90
N/A N=26 Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome
Postural Tachycardia Syndrome
Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL
N/A N=9 Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
Patients With Gastroparesis Who Have Failed Standard Therapy
Primary: Improvement of Overall Symptoms Based on Likert Scale — 2 Participants
Phase 2 N=96 Buspirone for Early Satiety and Symptoms of Gastroparesis
Gastroparesis
Primary: 4-Week Change in the Postprandial Fullness and Early Satiety Symptoms Severity — -1.16; -1.03 score on a scale — p=0.69
N/A N=5 Pancreatic Enzymes to Restore Digestive Function in Malnourished Gastric Bypass Patients
Obesity
Primary: Fat Absorption — 60.6 g/d — p=<0.05
Phase 2 N=79 Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
Gastroparesis
Primary: Gastric Half Emptying Time (GEt1/2) — 131.2; 106.5; 118.2; 131.1 Minutes
N/A N=8 The Effect of Macronutrients on Satiety and Gut Hormone Responses
Eating Behavior
Primary: The Effect of Proteins on the Secretion of Gut Hormones From Different Parts of the Gastrointestinal Tract — 1310; 1073; 1118; 1188 pg*min/mL
Phase 3 N=58 Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
Gastroparesis
Primary: Symptom of Vomiting Associated With Gastroparesis — 1.82; 2.68; 0.17; 1.20 Patient Self-reported Symptom Score
Phase 1 N=38 A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Time Required for 50% of Radioactivity To Be Emptied From the Stomach by Scintigraphy — 1.44; 1.72; 1.41; 3.77 hours
Phase 1 N=36 A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide
Overweight · Obesity · Diabetes Mellitus, Type 2
Primary: Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)]…
N/A N=34 Food Preference Following Bariatric Surgery
Obesity
Primary: Total Food Intake (Lunch Buffet) at 24 Months — 2540.1; 721 kJ
Phase 4 N=11 The Effect of Glucomannan Soluble Fiber on Glucose Homeostasis in Patients With Roux En Y (RNY) Gastric Bypass Surgery
Hypoglycemia
Primary: Difference Score: Percent of Time Spent in Hypoglycemic State — 1.2 Difference score, trt-control (percent) — p=0.99
N/A N=29 Exendin-9,39 and Satiety After Bariatric Surgery
Obesity
Primary: Caloric Intake — 531; 465; 444; 494 calories
Phase 4 N=60 Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
Diabetes Mellitus, Type 2 · Obesity · Gastroparesis
Primary: Presence of RGV (Residual Gastric Volume) in Stomach — 7; 1 Participants
Phase 2 N=393 Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis
Diabetes Mellitus · Diabetes Mellitus Complications · Gastroparesis
Primary: Change From Baseline to Week 12 in Weekly Vomiting Episodes — 5.7; 7.7; 6.9; 4.8 vomiting episodes per week — p=0.36
Phase 2 N=114 A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Gastroparesis
Primary: Percentage of Responders Based on the Fullness/Early Satiety Subscale (Responders) as Assessed by Gastrointestinal Cardinal Symptom Index-Daily Diary (GCSI-DD) at Week…
N/A N=374 The Primary Symptoms of GERD(Gastroesophageal Reflux Disease) in Chinese Outpatients in Gastroenterology Department
Gastroesophageal Reflux
Primary: The Primary Symptom of GERD in Chinese Outpatients in Gastroenterology Department — 19; 30; 42; 23 Participants
Phase 2 N=27 Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers
Healthy Volunteer
Primary: Fasting Gastric Volume as Measured by Single Photon Emission Computed Tomography (SPECT) — 178.8; 191.1 mL
N/A N=9 Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.
Gastroparesis
Primary: Gastric Accommodation — 322.22; 402.78; 450.63 ml
Phase 3 N=20 Effects of Gastric Bypass on Blood Levels of Duloxetine
Bariatric Surgery
Primary: Cmax — 51.04; 61.41 ng/ml